HOME > BUSINESS
BUSINESS
- Ono Licenses Pheochromocytoma Treatment Metyrosine from Valeant
October 24, 2013
- Swiss Novartis Sees 22% Plunge in January-September Diovan Sales
October 23, 2013
- Shionogi, Nipro to Copromote Anti-Influenza Treatment Rapiacta
October 23, 2013
- Roche Still Tops in Patent Asset Ranking in Japan, Shionogi, MTPC Jumps to Second, Third Place
October 22, 2013
- Wholesalers’ Sluggish Price Settlement Rate Could Mar Reliability of Market Price Survey
October 22, 2013
- BMKK, Pfizer to Change Distribution Channel to Wholesalers for Eliquis, Remain as Copromoters
October 21, 2013
- CMIC Holdings Joins Hands with UK Firm Aesica in Contract Manufacturing Biz
October 21, 2013
- Santen Opens Office in Ho Chi Minh City
October 21, 2013
- Kissei, Kyorin Initiate PI Study of Overactive Bladder Treatment KEA-0447/KRP-EPA605
October 21, 2013
- Teva Pharma Japan to Discontinue Marketing 15% of All Products Under Selection and Concentration Strategy
October 18, 2013
- Amgen Making Fresh Start in the Japanese Market through Joint Venture with Astellas; Pathway to Independent Operation Remains Nebulous
October 18, 2013
- Eisai Inc to Increase Belviq Sales Reps to 400 in US
October 17, 2013
- Toho Pharmaceutical’s Logistics Base TBC Sapporo Starts Operations: Toho Holdings
October 17, 2013
- NBI, Eli Lilly Submit NDA for SGLT-2 Inhibitor
October 17, 2013
- Gilead to Fully Enter Japan, File for Approval for Hepatitis C Treatment Sofosbuvir in 2014: President
October 16, 2013
- Otsuka Completes Acquisition of US Biotech Startup Astex
October 16, 2013
- Janssen, AZ to Copromote Prostate Cancer Treatment Abiraterone in Japan
October 16, 2013
- Once-Weekly DPP-4 Inhibitors of MSD, Takeda to Bring New Dimension to Packed Market
October 15, 2013
- Santen Launches Preservative-Free Tapros Mini Ophthalmic Solution
October 15, 2013
- Kowa Files for Approval of Glaucoma Treatment K-115
October 15, 2013
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…